Test Price
2,800 AED✅ Home Collection Available
MYBPC1 Gene Lethal Congenital Contracture Syndrome Type 4 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين MYBPC1 لمتلازمة التقفع الخلقي المميتة من النوع الرابع في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary – الامتثال للوائح الصحية الإماراتية
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with a DHA-licensed physician.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
ملخص تنفيذي: يضمن هذا الاختبار أعلى معايير الدقة من خلال معمل معتمد ISO 9001:2015 بالتوافق مع القانون الاتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية الإماراتي.
Overview
The MYBPC1 gene test detects mutations causing Lethal Congenital Contracture Syndrome Type 4, a severe autosomal recessive disorder presenting at birth with multiple joint contractures and muscle atrophy. التحليل الجيني لجين MYBPC1 يكشف الطفرات المسببة لمتلازمة التقفع الخلقي المميتة من النوع الرابع، وهو اضطراب وراثي جسدي متنحٍ شديد يظهر عند الولادة مع تقفعات متعددة في المفاصل وضمور عضلي.
| Feature | Our Test (NGS Targeted Sequencing) | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision | 100% coverage of MYBPC1 coding regions with >99.9% sensitivity | Broader analysis but lower depth; variants may be missed |
| Methodology | NGS (Next Generation Sequencing) with Sanger confirmation | Whole exome NGS, often without dedicated coverage compensation |
| Turnaround Time | 3 to 4 Weeks | 6–12 Weeks (often longer due to incidental findings analysis) |
| Cost | 2800 AED | 4200–6000 AED typical |
Physician Insight & Safety Protocol
“Understanding the gravity of a potential diagnosis like Lethal Congenital Contracture Syndrome is crucial; this test must be interpreted with compassion and clinical correlation, alongside a multidisciplinary team including clinical geneticists and neonatologists. Always ensure results are discussed in a confidential, supportive setting with expert genetic counselling.”
— Dr. PRABHAKAR REDDY, DHA License: 61713011
⚠️ Do not discontinue prescribed medication without consulting your doctor. This test does not replace clinical management.
Exclusion Criteria & Emergency Red Flags
- Not indicated for asymptomatic adults without a confirmed family history of MYBPC1-related myopathy.
- ER Red Flags: Sudden worsening of joint contractures, respiratory distress in neonates, severe feeding difficulties or failure to thrive.
- Specimen rejection: Improperly stored FTA card or clotted whole blood; recollection will be arranged at no extra charge.
- ملاحظة السلامة: لا يُستخدم الاختبار كبديل عن التقييم السريري العاجل؛ في حالة ظهور أعراض تنفسية حادة يُرجى التوجه فوراً إلى أقرب مستشفى.
Patient FAQ & Clinical Guidance
1. What is the purpose of the MYBPC1 gene test?
This NGS test identifies pathogenic variants in the MYBPC1 gene to confirm a diagnosis of Lethal Congenital Contracture Syndrome Type 4. It is typically ordered for newborns or infants presenting with multiple joint contractures, muscle atrophy, and respiratory insufficiency, enabling precise genetic counselling and family risk assessment. يهدف هذا الاختبار إلى تأكيد التشخيص الجيني لمتلازمة التقفع الخلقي المميتة من النوع الرابع عند الأطفال الذين يظهرون تقفعات مفصلية وضعفًا عضليًا.
2. How is the sample collected?
A small amount of whole blood or a drop on an FTA card is collected via painless venipuncture at home or in a clinic. Our DHA-certified phlebotomists follow cold-chain protocols, and collection can be scheduled between 8 AM and 11 PM daily. يتم جمع العينة بواسطة فني مختص معتمد من هيئة الصحة بدبي، إما بسحب عينة دم وريدية أو باستخدام بقعة دم على بطاقة FTA.
3. How accurate is the test?
With >99.9% sensitivity and specificity under ISO 9001:2015 accredited NGS, results exceed international diagnostic standards. Every pathogenic variant is confirmed by Sanger sequencing to eliminate false positives. تبلغ دقة الاختبار أكثر من 99.9% من حيث الحساسية والنوعية، مع اعتماد ISO وتأكيد بالطرق التكميلية.
Specimen & Pre-Test Requirements
- Sample Types: Whole Blood (preferred), Extracted DNA, or One Drop of Blood on FTA Card.
- Pre-: Clinical history of the patient, a genetic counselling session to draw a pedigree chart of family members affected with MYBPC1-associated Lethal Congenital Contracture Syndrome Type 4. No medication changes are required.
المتطلبات السابقة للاختبار: التاريخ السريري وجلسة استشارة وراثية لرسم شجرة العائلة. - TAT: 3 to 4 Weeks from receipt at the laboratory.
Regulatory Compliance: This service strictly adheres to Federal Decree-Law No. 41 of 2024 (Article 87) on Medical Liability, the UAE Child Digital Safety (CDS) Law 2026 for minors’ health data, and UAE Personal Data Protection Law (PDPL). All genetic data is processed with encryption and stored locally in UAE sovereign cloud infrastructure.
Facility License: 9834453 | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | DHA Lab Accreditation.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians